Ballantyne, Christie M.

Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide

Pokharel, Y., Tang, F., Jones, P. G., Nambi, V., Bittner, V. A., Hira, R. S., Nasir, K., Chan, P. S., Maddox, T. M., Oetgen, W. J., et al. (2017) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthClinical practice guidelines implementation

Cited by 107

Reproducibility and Variability of Protein Analytes Measured Using a Multiplexed Modified Aptamer Assay

Tin, A., Yu, B., Ma, J., Masushita, K., Daya, N., Hoogeveen, R. C., Ballantyne, C. M., Couper, D., Rebholz, C. M., Grams, M. E., et al. (2019) · The Journal of Applied Laboratory Medicine

Advanced Biosensing Techniques and ApplicationsAdvanced biosensing and bioanalysis techniques

Cited by 106

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

Watts, G. F., Schwabe, C., Scott, R., Gladding, P. A., Sullivan, D., Baker, J., Clifton, P., Hamilton, J., Given, B., Melquist, S., et al. (2023) · Nature Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 105

Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials

Bays, H. E., Banach, M., Catapano, A. L., Duell, P. B., Gotto, A. M., Laufs, U., Leiter, L. A., Mancini, G. B. J., Ray, K. K., Bloedon, L. T., et al. (2020) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug Reactions

Cited by 103

Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other Statins

Stein, E. A., Ballantyne, C. M., Windler, E., Sirnes, P. A., Sussekov, A., Yigit, Z., Seper, C., & Gimpelewicz, C. R. (2008) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 102

New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs

Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 99

Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Jiao, L., Tardif, J.-C., Gregson, J., Pocock, S. J., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 97

A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk

Williams, S. A., Ostroff, R., Hinterberg, M. A., Coresh, J., Ballantyne, C. M., Matsushita, K., Mueller, C. E., Walter, J., Jonasson, C., Holman, R. R., et al. (2022) · Science Translational Medicine

Lipoproteins and Cardiovascular HealthCardiovascular Health and Risk Factors

Cited by 97

Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)

Bays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology

Lipid metabolism and disordersFatty Acid Research and Health

Cited by 94

Comparison of Proteomic Measurements Across Platforms in the Atherosclerosis Risk in Communities (ARIC) Study

Rooney, M. R., Chen, J., Ballantyne, C. M., Hoogeveen, R. C., Tang, O., Grams, M. E., Tin, A., Ndumele, C. E., Zannad, F., Couper, D. J., et al. (2023) · Clinical Chemistry

Advanced Biosensing Techniques and ApplicationsAdvanced Proteomics Techniques and Applications

Cited by 77

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial

Nissen, S. E., Lincoff, A. M., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Ridker, P. M., Ray, K. K., McGuire, D. K., Mozaffarian, D., Koenig, W., et al. (2021) · JAMA Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 76

High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study

Filion, K. B., Agarwal, S. K., Ballantyne, C. M., Eberg, M., Hoogeveen, R. C., Huxley, R. R., Loehr, L. R., Nambi, V., Soliman, E. Z., & Alonso, A. (2015) · American Heart Journal

Atrial Fibrillation Management and OutcomesAcute Myocardial Infarction Research

Cited by 73

Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia

Davidson, M. H., Maki, K. C., Bays, H., Carter, R., & Ballantyne, C. M. (2009) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 71

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia

Gaudet, D., Clifton, P., Sullivan, D., Baker, J., Schwabe, C., Thackwray, S., Scott, R., Hamilton, J., Given, B., Melquist, S., et al. (2023) · NEJM Evidence

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 71

A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies

Brautbar, A., Pompeii, L. A., Dehghan, A., Ngwa, J. S., Nambi, V., Virani, S. S., Rivadeneira, F., Uitterlinden, A. G., Hofman, A., Witteman, J. C. M., et al. (2012) · Atherosclerosis

Genetic Associations and EpidemiologyNutrition, Genetics, and Disease

Cited by 71

Effect of Moderate Alcohol Consumption on Hypertriglyceridemia: A Study in the Fasting State

Pownall, H. J., Ballantyne, C. M., Kimball, K. T., Simpson, S. L., Yeshurun, D., & Gotto, A. M. (1999) · Archives of Internal Medicine

Alcohol Consumption and Health EffectsLipid metabolism and disorders

Cited by 70

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

Brinton, E. A., Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Braeckman, R. A., & Soni, P. N. (2013) · Cardiovascular Diabetology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 70

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial

Ballantyne, C. M., Gellis, L., Tardif, J.-C., Banka, P., Navar, A. M., Asprusten, E. A., Scott, R., Stroes, E. S. G., Froman, S., Mendizabal, G., et al. (2026) · JAMA

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 68

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 64

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction

Gaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 61

Dietary and Pharmacological Fatty Acids and Cardiovascular Health

Wu, H., Xu, L., & Ballantyne, C. M. (2020) · The Journal of Clinical Endocrinology & Metabolism

Fatty Acid Research and HealthNutritional Studies and Diet

Cited by 59

Triglycerides and ASCVD risk reduction: recent insights and future directions

Hussain, A., Ballantyne, C. M., Saeed, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 57

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 57

Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: ARIC Study

Florido, R., Kwak, L., Lazo, M., Nambi, V., Ahmed, H. M., Hegde, S. M., Gerstenblith, G., Blumenthal, R. S., Ballantyne, C. M., Selvin, E., et al. (2018) · Circulation

Physical Activity and HealthCardiovascular and exercise physiology

Cited by 56